IceCure Medical expands U.S. sales team after 70% install base growth

Go back to IceCure Medical expands U.S. sales team after 70% install base growth

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

July 14, 2026 8:32 AM EDT

CAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the expansion of its United States... More